Gout: one year in review 2023.

Abstract

Gout is a chronic joint disease caused by the deposition of monosodium urate crystals into and around the articular tissues. In the last two years, new insights regarding diagnosis, genetic involvement, pathogenesis, comorbidities, and clinical data, have allowed the identification of new strategies to improve the control of the disease and its flares. In keeping, the discover of new mechanisms concerning crystal-induced inflammation have suggested new ways for the management not only of gout, but also other systemic diseases, mainly including renal and cardiovascular disorders. In this context it is very representative the case of colchicine which, given the surprising results obtained both in laboratory and clinical experiments, has recently received by FDA the approval for the prevention of cardiovascular disorders.

• Authors: Leonardo Punzi, Paola Galozzi, Roberto Luisetto, Anna Scanu, Roberta Ramonda, Francesca Oliviero
• Journal: Clinical and experimental rheumatology (Clin Exp Rheumatol) Vol. 42 Issue 1 Pg. 1-9 (Jan 2024) ISSN: 0392-856X [Print] Italy
• PMID: 38306017 (Publication Type: Journal Article, Review)

Chemical References

• Uric Acid
• Gout Suppressants
• Colchicine

Topics

• Humans
• Uric Acid
• Gout (diagnosis, drug therapy, epidemiology)
• Gout Suppressants (therapeutic use)
• Colchicine (therapeutic use)
• Comorbidity